Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mufemilast - Tianjin Hemay Biotech

Next Previous
Drug Profile

Mufemilast - Tianjin Hemay Biotech

Alternative Names: Hemay 005; Phosphodiesterase 4 (PDE4) inhibitors - Tianjin Hemay Biotech

Latest Information Update: 25 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tianjin Hemay Biotech
  • Developer Ganzhou Hemay Pharmaceutical; Tianjin Hemay Biotech; Tianjin Hemay Pharmaceutical
  • Class 2 ring heterocyclic compounds; Acetamides; Anti-inflammatories; Antipsoriatics; Ketones; Phenyl ethers; Pyrroles; Skin disorder therapies; Small molecules; Sulfones; Thiophenes
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Behcet's syndrome; Plaque psoriasis
  • Phase II Ankylosing spondylitis; Atopic dermatitis; Ulcerative colitis
  • Phase I Chronic obstructive pulmonary disease; Psoriasis

Most Recent Events

  • 17 Feb 2025 Ganzhou Hemay Pharmaceutical completes a phase I bioequivalence trial for Psoriasis (In volunteers) in China (PO) (NCT06610903)
  • 25 Dec 2024 Phase-I clinical trials in Chronic obstructive pulmonary disease (In volunteers) in China (PO) (NCT06908642)
  • 12 Dec 2024 Ganzhou Hemay Pharmaceutical initiates a phase I pharmacokinetic trial in Psoriasis in China (NCT06610890)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top